Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY Putting It's Best Foot Forward

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Mar 14, 2023 10:50pm

183 Views

Post# 35338887

RE:RE:RE:RE:RE:RE:ONCY Putting It's Best Foot Forward

If ONC was really, truly deep in negotiations with mulitple Big Pharmas and they really, truly see vast potential in the forthcoming data release, then there would be NO WAY AF that ONC would be spending money on boiler room phoney articles directed at naive millenial speculators.

This reeks of desparation and little more than a sorry effort to prop up the SP long enough to milk the ATM and keep the gravy train rolling another year.

Grow up, and get serious Matt. Your company is 23 years old.

BOD... time for a new CEO, please!

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages